Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20470066 | 0.98 | FAAH (0.49) | FAAHCASP2CNR1TSHRRECQL | |
| SCHEMBL26208462 | 0.94 | CASP2 (0.53) | FAAHCASP2CNR1TSHRDNM1 | |
| SCHEMBL280231 | 0.92 | CASP2 (0.60) | FAAHCASP2CNR1TSHRRECQL | |
| SCHEMBL18714245 | 0.92 | FAAH (0.50) | FAAHCASP2CNR1TSHRDNM1 | |
| SCHEMBL24759152 | 0.91 | FAAH (0.59) | FAAHCASP2CNR1DNM1NAAA | |
| SCHEMBL18588287 | 0.91 | CASP2 (0.55) | FAAHCASP2CNR1DNM1NAAA | |
| SCHEMBL19477862 | 0.91 | CASP2 (0.58) | FAAHCASP2CNR1TSHRRECQL | |
| SCHEMBL21311575 | 0.91 | TSHR (0.56) | FAAHCASP2CNR1TSHRRECQL | |
| SCHEMBL15853379 | 0.91 | FAAH (0.49) | FAAHCASP2CNR1TSHRDNM1 | |
| SCHEMBL21234067 | 0.90 | FAAH (0.60) | FAAHCASP2CNR1TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | NEKTAR THERAPEUTICS (US) | 2012-10-11 | — | — | US | disclosed |
| US-8133865-B2 | Two polymer chains (especially polyethylene oxide) connected to each other through a fluorenedicarbamoylmethyl group, which in turn is connected to an amine active agent by a releasable carbamate linkage; increased in vivo half-life | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | ABCG2, SI, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FAAH 652/4885CASP2 4466/4885CNR1 1450/4885 |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | F8, F13A1, F13B | FAAH 2639/4885CASP2 4350/4885CNR1 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.